| Previous Close | 14.71 |
| Open | 14.70 |
| Bid | 14.49 x 0 |
| Ask | 14.69 x 0 |
| Day's Range | 14.47 - 15.65 |
| 52 Week Range | 0.81 - 26.25 |
| Volume | 21,784 |
| Avg. Volume | 89,340 |
| Market Cap | 273.477M |
| Beta (5Y Monthly) | 0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | Dec. 21, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- CNW Group
Pietro Fiorentini Acclaimed by Frost & Sullivan for Its Unrivalled Smart Gas Metering Solutions
Its advanced solutions, wide geographic footprint, and deep customer focus earn it a significant competitive advantage in the global marketLONDON, March 4, 2021 /CNW/ -- Based on its recent analysis of the global smart gas metering market, Frost & Sullivan recognizes Italy-based Pietro Fiorentini S.a with the 2021 Global Company of the Year Award.
- Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference)
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021.
- Business Wire
ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTopeâ„¢ Monoclonal Antibody Cocktail Candidate Against COVID-19
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals.
